When patients start tirzepatide (Zepbound) for obesity, the number on the scale is usually the most visible outcome. But obesity treatment is ultimately about health, not simply weight. A newly published analysis from the SURMOUNT clinical-trial program asks a useful question: how often do patients improve several important cardiometabolic measures at the same time?
What the new study examined
The August 2026 PLOS One report was a post hoc analysis of SURMOUNT-1 through SURMOUNT-4. Investigators evaluated three outcomes together: clinically meaningful weight loss, a reduction in systolic blood pressure of at least 5 mmHg, and a non-HDL cholesterol level below 130 mg/dL. The weight-loss component was tested at thresholds of at least 5%, 10%, and 15% of baseline body weight.
The results: improvement across several targets at once
Across the SURMOUNT trials, 32% to 38% of tirzepatide-treated participants achieved the composite endpoint when the weight-loss threshold was at least 5%, compared with 2% to 8% of placebo-treated participants. With a 10% weight-loss threshold, 28% to 37% of tirzepatide-treated participants achieved all three targets, versus 1% to 5% with placebo. Even when the weight-loss requirement was raised to at least 15%, 22% to 34% of tirzepatide-treated participants reached the combined target, compared with 1% to 3% with placebo.
These findings are consistent with the broader SURMOUNT experience: tirzepatide can produce substantial weight loss while also improving cardiovascular risk factors such as blood pressure and atherogenic cholesterol measures.
Why non-HDL cholesterol matters
Non-HDL cholesterol represents the cholesterol carried by potentially atherogenic lipoproteins. It is calculated by subtracting HDL cholesterol from total cholesterol and is often useful when assessing cardiovascular risk. A non-HDL cholesterol level below 130 mg/dL was one component of the study’s triple endpoint.
What this study does – and does not – prove
The analysis strengthens the case for looking beyond pounds lost when evaluating obesity treatment. A patient who loses weight while also improving blood pressure and lipid-related risk markers may be achieving a broader cardiometabolic benefit.
However, this was a post hoc analysis, not a trial designed primarily to prove that reaching this composite endpoint prevents heart attacks, strokes, or cardiovascular death. The authors explicitly note that cardiovascular-outcomes research in obesity is ongoing. The appropriate conclusion is that tirzepatide was associated with simultaneous improvement in several clinically relevant risk factors – not that this particular analysis proves fewer cardiovascular events.
What this means for patients taking Zepbound
Weight remains an important treatment measure, but it should not be the only one. Depending on a patient’s medical history, follow-up may also include blood pressure, waist circumference, glucose measures, cholesterol and other laboratory values, medication tolerability, nutrition, physical function, and maintenance planning.
This broader view is particularly important for patients who begin treatment with hypertension, dyslipidemia, prediabetes, sleep apnea, or other obesity-related complications. Successful weight management should ideally improve the health problems that accompany excess weight, not merely change the scale.
BeLite Clinical Perspective
The practical message is straightforward: do not judge an obesity medication only by the percentage of body weight lost. The better question is whether treatment is improving the patient’s overall risk profile while remaining tolerable and sustainable. Tirzepatide can be a powerful tool, but medication choice and dose still need to be individualized.
Frequently Asked Questions
Does Zepbound (tirzepatide) help with more than weight loss?
Clinical-trial analyses show that tirzepatide can improve several cardiometabolic measures in addition to body weight, including blood pressure and lipid measures. In the new SURMOUNT analysis, substantially more tirzepatide-treated participants reached weight-loss, systolic blood-pressure, and non-HDL cholesterol targets at the same time than placebo-treated participants. Individual results vary, and these findings do not mean every patient will reach all three targets.
How much did systolic blood pressure have to improve in this study?
The composite endpoint required a reduction in systolic blood pressure of at least 5 mmHg. This was assessed together with a specified amount of weight loss and a non-HDL cholesterol level below 130 mg/dL.
What is non-HDL cholesterol?
Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It captures cholesterol carried in potentially atherogenic lipoproteins and can be useful when assessing cardiovascular risk. In this analysis, a non-HDL cholesterol level below 130 mg/dL was one component of the combined endpoint.
Does this study prove that tirzepatide prevents heart attacks or strokes?
No. This analysis evaluated weight loss and cardiovascular risk factors, not whether tirzepatide reduced the number of heart attacks, strokes, or cardiovascular deaths. Improvements in blood pressure and cholesterol are clinically meaningful, but they should not be presented as direct proof of fewer cardiovascular events.
If my blood pressure or cholesterol improves on tirzepatide, can I stop those medications?
Not without discussing it with the clinician managing those conditions. Weight loss may change blood-pressure or lipid-treatment needs, but medication changes should be based on repeated measurements, the patient’s overall cardiovascular risk, other medical conditions, and the prescribing clinician’s judgment.
Related BeLite Resources
How BeLite Can Help
At BeLite Medical Center, weight-management treatment is medically supervised and individualized. We consider medication response together with tolerability, nutrition, exercise, medical history, and relevant health measures rather than treating weight as an isolated number.
Learn more about BeLite Medical Center and scheduling a free consultation.
References
Sattar N, et al. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: a post hoc analysis from the SURMOUNT trials. PLOS One. Published August 13, 2026.
BeLite can help patients translate emerging obesity-medicine evidence into an individualized plan that considers efficacy, tolerability, nutrition, muscle preservation, long-term maintenance, and access.BeLite Medical Center has provided physician-supervised medical weight management in Fairfax, Virginia since 1995. Our clinic offers in-person medical supervision — with the ability to adjust medications and monitor your progress in real time — that fully virtual services cannot match.Booking appointments is simple with our online scheduling portal, available 24/7. You can also call or text us at (703) 359-9200, or email belitemed@gmail.com. We offer free consultations for new patients — if you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time
Medical Disclaimer
This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the readers own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.
Reviewed by Richard Rothman, MD, PhD — Medical Director, BeLite Medical Center.
